Login
Moderna, Inc. logo

Moderna, Inc.

modernatx.com

What Do They Do?

Sells COVID and RSV vaccines to governments and commercial buyers, while developing mRNA vaccines and treatments for infectious diseases, cancer and rare diseases.

How Do They Make Money?

Customers pay for COVID and RSV vaccines, with product sales counted when the vaccines are delivered. Other revenue comes from research grants, collaboration work, licenses and royalties, and manufacturing-capacity agreements; payment timing varies by arrangement.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Net product sales
Sold outright

94%
FY2022: 96%
Other revenue
6.5%

Who Are Their Customers?

Moderna sells vaccines to commercial buyers, foreign governments and international organizations. In the U.S., wholesalers and distributors are the main route to market, with some direct sales to retailers and healthcare providers; it also works with government entities, grant organizations and strategic collaborators.

Do Revenues Turn Into Profits?

No. It lost $2.8B in FY2025.

Operating income, FY2025
−158% of revenue
▲ +22% (Loss) vs FY2024 (−$3.9B, −122%)
Net income, FY2025
−145% of revenue
▲ +21% (Loss) vs FY2024 (−$3.6B, −110%)
Free cash flow, FY2025
−106% of revenue
▲ +49% (Loss) vs FY2024 (−$4.1B, −125%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +29%
vs $1B in Q3 FY2025
Net income
▲ Turned profitable
vs −$200M in Q3 FY2025
Net product sales share of revenue vs 95.8% in Q3 FY2025
  • Nov 6, 2026 Moderna raised its 2026 revenue growth outlook to 15%–25%. It also received U.S. approval for its seasonal flu vaccine and approval in Canada for its flu/COVID combination vaccine.
  • Mar 3, 2026 Moderna settled worldwide patent litigation over its infectious disease vaccines. It agreed to pay $950 million and could owe a further contingent payment; the settlement grants a royalty-free license for covered vaccines.

Shrinking. Revenue fell 89% in 4 years, from $18.5B in FY2021 to $1.9B in FY2025, about 43% a year.

Commercial products The older report described Spikevax as its first approved product and focused on the potential launch of RSV, flu and combination vaccines. The latest report lists three commercial products, including COVID and RSV vaccines, and describes a broader pipeline spanning infectious disease, oncology and rare disease.

Revenue over time
Net product sales Other revenue Grant revenue Collaboration revenue
$20B$10B$0

Who Do They Compete With?

Competes with Pfizer, BioNTech, Sanofi, Novavax, and GlaxoSmithKline

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support